Objective: To evaluate the impact of fluconazole prophylaxis on the incidence of fungal infections and on mortality among critically ill surgical patients.
F ungal infections are a growing challenge in the care of critically ill patients. During the last 2 decades, the incidence of candidemia in the intensive care unit (ICU) has increased exponentially (1, 2) . Candidal isolates account for a rising proportion of nosocomial bloodstream infections and represent the fourth-mostcommon cause of catheter-related infection (1) (2) (3) . The burden of fungemia appears particularly high in surgical patients. A recent prospective, observational study reported that the incidence of fungemia in surgical ICU (SICU) patients approached ten cases per 1,000 admissions (4) . Surgical patients are likely at higher risk for fungemia and candidal infections because of their underlying severity of illness, impaired gastrointestinal mucosal integrity, and frequency of treatment with both broad-spectrum antibiotics and parenteral nutrition (3, 4) .
Underscoring the burden of candidemia in the ICU is the mortality associated with these infections. Multiple reports document unadjusted mortality rates of between 25% and 50% among SICU patients with candidemia (1) (2) (3) (4) . Controversy exists about the mortality attributable to candidemia; some studies document attributable mortality rates reaching 30%. Other researchers such as Blot et al. (5, 6) , using different matching techniques, have alternatively concluded that candidemia does not lead to attributable mortality. Irrespective of this discordance, several investigations have demonstrated its significant impact on resource utilization and length of stay (2, 3) .
Coincident with the rise in rates of fungemia has been a shift in the pattern of candidal isolates recovered from the ICU. In the past, Candida albicans represented the fungus most frequently isolated from the bloodstream. Now, however, nonalbicans species, such as Candida glabrata, Candida krusei, and Candida tropicalis, account for approximately half of candidal infections in critically ill adults (1) (2) (3) (4) . The susceptibility of these nonalbicans species to fluconazole is variable; generally, C. krusei is fluconazole-resistant and C. glabrata is susceptible in a dose-dependent fashion. Additionally, optimal dosing regimens of fluconazole for treatment of fungemia in critically ill subjects remain controversial (3) .
Because of both the burden associated with treating invasive candidal infections and the cost of treatment, some advocate a strategy based on prophylaxis (8) . Through identification of patients at high risk for candidal infections, as is done with solid organ and hematopoietic stem cell transplant recipients, proponents of antifungal prophylaxis argue that this approach can improve outcomes. Greater use of antifungal prophylaxis, however, must be balanced against the potential for this to promote resistance to standard treatment options. More troubling, antifungal prophylaxis might affect the types of fungal isolates seen in the ICU. For example, at some centers, broader use of fluconazole prophylaxis in hematologic malignancies has reduced the prevalence of C. albicans infections but has simultaneously led to an increase in infections due to nonalbicans species (9, 10) .
To date, few studies have expressly explored antifungal prophylaxis in critically ill patients. Although these reports suggest that in select patients prophylaxis might lower rates of fungal infection, the effect on mortality is less clear. To better assess the value of antifungal prophylaxis on outcomes and mortality among critically ill individuals, we conducted a metaanalysis of randomized trials in this area. We hypothesized that although prophylaxis would reduce the rate of fungal infections, it would not alter mortality.
METHODS
Search Strategy. We searched MEDLINE (1966 to December 2004), EMBASE (January 1990 to December 2004), and the Cochrane Library to identify prospective, randomized trials of antifungal prophylaxis in critically ill surgical patients. We limited our focus to surgical patients because they are considered at high risk for candidal infections and because this would enhance the qualitative homogeneity of the meta-analysis. Because of the few trials concerning this topic, we revised our criteria and expanded them to include reports in which at least half of the randomized population comprised surgical patients. To be comprehensive, we also hand-searched the abstracts from the annual meetings (1998 to 2004) of the American Thoracic Society, the Society for Critical Care Medicine, the European Society for Intensive Care Medicine, the Infectious Diseases Society of America, and the Interscience Committee for Antimicrobial Agents and Chemotherapy. We additionally attempted to locate potentially relevant trials by reviewing the references of the selected articles and by contacting experts in the field. We had no language restrictions. We utilized the following key words in the search strategy: Candida, candidemia, critical care, fluconazole, fungus, fungal, intensive care, preven-tion, prophylaxis, and surgery. To be included in our meta-analysis, studies had to enroll only critically ill patients and not include subjects who were receiving fluconazole prophylaxis for another reason (e.g., intercurrent immunosuppression, recent chemotherapy, or following organ transplantation). We excluded studies that were not randomized and that did not employ fluconazole. We further excluded investigations of antifungal therapies that were combined as part of a regimen for selective digestive decontamination solely for the prevention of nosocomial pneumonia. Two investigators independently reviewed each potential abstract and article to ensure that it met the inclusion criteria.
Study Evaluation and Data Abstraction. Two investigators also independently rated the quality of the trials. Since no objective rubrics exist for assessing the quality of randomized studies of antifungal prophylaxis, we relied on the scoring system developed by Jadad et al (11) . Data were extracted from relevant reports in duplicate. In addition to noting the precise antifungal prophylaxis regimen given, we specifically recorded the types of subjects studied, their severity of illness, and the baseline fungal colonization rate among study participants. We further culled information regarding the use of mechanical ventilation and parenteral nutrition in the study arms. Both the rate of fungal infections and mortality represented end points of interest. We recorded the types of fungal infections and the distribution of candidal species isolated. If it were included in the report, we collected data regarding resource utilization and ICU length of stay. Finally, we examined the safety of fluconazole and reports of adverse events during the trials.
Sensitivity Analysis. Because our search reviewed few studies meeting our entry criteria, we reanalyzed our findings and subsequently included results from two additional trial reports describing fluconazole use in the ICU. One of these trials included both surgical and nonsurgical patients and did not precisely deal with prophylaxis alone. In order to be consistent with our focus on SICU patients, we incorporated only the data from this study dealing with patients with intraabdominal processes. We limited our sensitivity analysis to the effect of fluconazole on mortality.
Statistics. To evaluate whether publication bias might impact our observations, we created funnel plots and calculated the Begg's statistic. The statistic was used to measure agreement between the two investigators in their quality ratings of the clinical trials. We utilized risk differences as computed on the basis of the odds ratios from each of the randomized trials and their respective 95% confidence intervals (CIs) to determine the impact of antifungal prophylaxis on the rate of fungal infections and on mortality. Heterogeneity was assessed visually with Galbraith plots as well as with Q statistics (chi-square) by means of the methods of Mantel and Haenszel. We employed a random-effects model (Der Simonian and Laird) and computed summary odds ratios to illustrate the relationship between antifungal prophylaxis and both fungal infection and mortality. All analyses were completed with the Stata statistical package (College Station, TX).
RESULTS
Primary Analysis. Of 52 potential studies reported, 48 were excluded for the following reasons: observational, retrospective, or uncontrolled study (n ϭ 41); pharmacokinetic study (n ϭ 2); utilized ketaconazole rather than fluconazole (n ϭ 2); studied nystatin (n ϭ 2); administered fluconazole empirically to patients with sepsis (n ϭ 1); or gave fluconazole to both critically ill and noncritically ill individuals (n ϭ 1). Review of abstracts from national meetings identified no unpublished trials. Hence, our search yielded four randomized trials comparing fluconazole to placebo for antifungal prophylaxis in the ICU (12) (13) (14) (15) . The size of the studies varied (range, 43 to 260 patients) and included a total of 626 subjects. All focused mainly on individuals in the SICU, and three expressly excluded persons admitted to the ICU following organ transplantation. In the study by Pelz (14), 2.3% of subjects had undergone a transplantation. In the investigation of Garbino et al. (15) , both medical ICU and SICU subjects were included, but the status of more than half was postoperative. These authors did not stratify results by patient type (surgical vs. purely medical); hence, we could not extract data on only those in the SICU. Each trial was double-blind, and two represented multicenter efforts. In general, the quality of these investigations was high (median Jadad score, 6), and there was strong interrater agreement in the quality ratings ( ϭ 0.95; p Ͻ .001). Neither the Begg's statistic (0.734) nor review of the funnel plot suggested publication bias. Table 1 demonstrates the key features of the included trials. Although each involved SICU patients, enrollment criteria varied and reflected differing efforts to identify persons at high risk for fungal infection. One protocol included only patients with a recurrent perforation or gastric leak (12) . The others based enrollment in the trial on ICU length of stay (Ͼ48 or Ͼ72 hrs) (13) (14) (15) . There was also substantial heterogeneity among the trials with respect to fluconazole dosing. One group of investigators gave 400 mg daily, whereas two other studies dictated an initial loading dose of 800 mg, followed by administration of 400 mg daily (12) (13) (14) . The trial by Garbino et al. utilized 100 mg of fluconazole daily (15) . Moreover, route of fluconazole administration varied: one protocol required that the drug be given intravenously, and two mandated that the drug be given orally. In another, subjects able to tolerate oral feeding received fluconazole enterally; if not, the medication was delivered intravenously. Patients remained on a prophylactic fluconazole regimen until development of a fungal infection, death, ICU discharge, or resolution of the underlying condition (e.g., the gastric leak). Only one study observed patients after ICU discharge (14) . This non-ICU observation period, however, was limited to 3 days. Definitions of fungal infections were homogeneous in the studies for bloodstream infection but not for the diagnosis of other types of fungal processes. For example, some investigators excluded funguria from outcomes measures because they felt it did not represent a severe infection (15) . Others recorded funguria and defined it on the basis of two positive urine cultures despite a change of catheter (14) . Table 2 shows the baseline characteristics of the patients enrolled in these trials. Nearly all subjects required mechanical ventilation. Both utilization of parenteral nutrition and the baseline candidal colonization, however, fluctuated substantially across the studies. For example, in the study by Pelz and coworkers (12), only 8.5% of subjects received parenteral nutrition, compared with approximately half of those studied by Eggimann et al (14) . Similarly, only three reports noted the rate of fungal colonization in patients at study enrollment; this ranged from 39.5% in the latter study to 76.9% in the former (12, 14, 15) . Randomization ensured that the severity of illness was comparable between the fluconazole and placebo arms within each trial. Mean Acute Physiology and Chronic Health Evaluation (APACHE II) scores extended from a low of 13 to a high of approximately 19.
The incidence of subsequent fungal infections ranged from 15.4% to 35.0% among placebo-treated patients and 5.8% to 13.3% among individuals given fluconazole. The differences seen in rates of fungal infection reached statistical significance in all but the study by Ables et al (13) . Figure 1 demonstrates the pooled point estimate for the odds ratio (OR) for fungal infections associated with fluconazole prophylaxis. Randomization to fluconazole prophylaxis reduced the rate of new fungal infections by nearly 55% (pooled OR, 0.44; 95% CI, 0.27-0.72; p Ͻ .001). The Q statistic (test for heterogeneity) equaled 1.456 (p ϭ .692). The impact of fluconazole was most pronounced on the incidence of urinary tract infections and peritonitis. The effect of fluconazole prophylaxis on bloodstream infections was more limited, and there was no statistically significant correlation between pharmacologic prevention and the frequency of candidemia. Only in the trial by Garbino et al. (15) did fluconazole result in a statistically significant reduction in candidemia. However, pooling the incidence of candidemia across all the studies, irrespective of randomization arm, reveals that this was generally rare. Among all 626 subjects in both the placebo and intervention arms, there were only 14 cases of candidemia (2.2% overall: 11 cases among the treated patients and three among the untreated subjects). Ten of these cases were in one trial; therefore, among the remaining studies, the frequency of candidemia was low. The efficacy of fluconazole also seemed dependent not only on the type of infection in question but also on the species of Candida. Fluconazole administration led to a significant reduction in C. albicans infections (pooled OR, 0.51; 95% CI, 0.30 -0.87; p ϭ .014). Although fluconazole decreased the risk of nonalbicans candidal infections to a similar degree, this difference did not reach statistical significance (p ϭ .10).
Despite the fact that fluconazole prophylaxis resulted in a substantial decrease in fungal infections, this was not associated with improved survival. Among placebo-treated patients, ICU mortality ranged from 10.8% to 38.8%. In those given fluconazole there was also substantial variability in death rates (12.3% to 50.0%). Figure 2 shows the overall lack of an effect of fluconazole on ICU mortality. The pooled OR for death was 0.87 (95% CI, 0.59 -1.28; p ϭ NS).
With respect to resource utilization, the median ICU length of stay in the trial by Eggimann et al. (12) was 22 days for those randomized to fluconazole, vs. 33 days for those given placebo. Pelz and co-workers (14) reported a median ICU length of stay of 5 days in both the fluconazole and placebo cohorts. In neither trial were any differences in length of stay statistically different. No report described other resource-utilization measures such as duration of mechanical ventilation, antibiotic-free days, or costs.
Sensitivity Analysis. As noted earlier, to increase our statistical power, we conducted a sensitivity analysis and included the data from two protocols (Tables 1 and 2) we initially excluded from evaluation (16, 17) . Methodologically and qualitatively, these other trials were distinct from the original four we reviewed. The first enrolled patients with a gastric perforation, irrespective of whether they were critically ill (16) . For this trial of 109 patients, participants randomized to placebo received one 200-mg dose of fluconazole intraoperatively. In the other investigation, Jacobs et al. (17) administered fluconazole (200 mg daily) to pa-tients with septic shock of unknown etiology. Prospectively, patients were stratified as to whether nosocomial pneumonia or an intraabdominal infection caused the septic shock. We extracted information only on those with intraabdominal processes. Notably, in this study, use of fluconazole in intraabdominal sepsis significantly enhanced survival.
Pooling the findings from these other studies with findings in the originally selected trials did not demonstrate that fluconazole prophylaxis affected overall mortality. For all six studies (Fig. 3) , comprising 779 subjects, the OR for death equaled 0.73 (95% CI, 0.52-1.06; p ϭ .10; Q ϭ 6.989 on 5; p ϭ .221) Excluding a study by Sandven and co-workers (because of its unique inclusion criteria and dosing of fluconazole) and analyzing the five remaining trials yielded an OR for death of 0.76 (95% CI, 0.53-1.13; p ϭ .15).
Safety. Three studies analyzed the safety of fluconazole prophylaxis. In general, the drug was well tolerated. The rates of laboratory abnormalities were similar across all the reports and did not differ between intervention and placebo arms. No deaths were attributed to fluconazole administration, and in only five patients (two fluconazole and three placebo recipients) was the intervention stopped because of toxicity concerns.
DISCUSSION
This meta-analysis demonstrates that there have been few well-done randomized trials of fluconazole prophylaxis in critically ill surgical patients. Additionally, no single dosing regimen for prevention has been consistently studied, and investigators have employed differing a APACHE III rather than APACHE II score; b secondary studies were included in the sensitivity analysis as described in the text; c only patients with intraabdominal infections were included in the meta-analysis; d although baseline use of MV was not reported, presumably all patients were on MV since all were in shock. strategies to identify subjects at high risk for candidal infections. Despite these limitations, fluconazole appears to significantly reduce the risk for candidal infections. However, this does not appear to be associated with a survival advantage, and the data are insufficient to comment on the impact of a prophylactic strategy on resource utilization.
The absence of an effect on mortality might reflect several factors. First, the pooled sample size may have been inadequate for detecting an influence on mortality. With additional research on greater numbers of patients, fluconazole prophylaxis could potentially be shown to result in a survival advantage. However, to address concerns regarding sample size and statistical power, we conducted a sensitivity analysis and included other trials in this area. Moreover, one of these reports actually noted improved survival with fluconazole use. Despite both increasing the potential pool of patients analyzed and biasing our analysis in favor of fluconazole by including the trial by Jacobs and colleagues (17) , we still failed to detect an impact on survival. Our inability to detect a survival advantage with fluconazole should therefore be interpreted with caution. Fluconazole could improve survival but simply may have been insufficiently studied thus far. Conversely, this approach might have been applied in a population not at adequately high risk to show a benefit. Second, and more likely, it may be unreasonable to assume that prevention of fungal infections will affect mortality. Preventing fungal infections may only alter the mode of death but not actual death rates. In other words, individuals may "die with but not of" fungal infections, and candidal infections may not be associated with an attributable mortality in the ICU. For example, in a matched case-control study carefully adjusting for age, severity of illness, and underlying disease, Blot et al. (5, 6) concluded that candidemia did not significantly affect mortality in the ICU. Similarly, in immunosuppressed individuals, routine fluconazole administration is not consistently associated with superior survival. Although several prospective, randomized, placebo-controlled studies of fluconazole administered to persons with hematologic malignancies or those undergoing bone marrow or stem cell transplantation demonstrate the efficacy of fluconazole at preventing both superficial and invasive candidal infections, few have shown a positive effect on mortality. Essentially, the evidence that this approach alters survival is from meta-analyses (18 -21) .
Third, in the studies of fluconazole prophylaxis for immunosuppressed subjects that do indicate a survival advantage, patients generally continued the medication for extended periods (e.g., weeks) and were followed for several months after enrollment (22, 23) . In the critical care trials reviewed in our analysis, fluconazole was prescribed for shorter durations (12) (13) (14) (15) . More important, the observation period following randomization was limited basically to the duration of the ICU stay. What transpires in the ICU has implications for the patient after ICU discharge. Therefore, the absence of a mortality effect may have arisen because the follow-up period was simply too short. Finally, fluconazole prophylaxis seems most effective at preventing non-bloodstream infections. The burden of these less invasive processes in terms of mortality, morbidity, and resource utilization is unclear. Notably, isolated funguria may not affect any clinically relevant outcome in the ICU, as long as it does not lead to systemic dissemination (24 -26) . Hence, preventing funguria and like infections may not reflect a clinically significant end point. In turn, it is unclear if combining these types of infections with bloodstream infections in one composite end point for a clinical trial is appropriate. Therefore, we examined candidemia separately. In focusing on bloodstream isolates, we did not observe an effect of fluconazole of candidemia. Admittedly, the rate of candidemia in both placebo and intervention arms was low. The low incidence of candidemia, however, may indicate a limited role for routine fluconazole prophylaxis in the SICU. This population, unlike immunosuppressed subjects, does not seem at sufficiently high risk for invasive infections for antifungal prophylaxis to prove beneficial. One group of experts suggests that prophylaxis will likely be advantageous if the rate of candidemia is at least 10% (3). In contrast, we noted an overall incidence of candidemia of Ͻ 3%. Alternatively, as some speculate, fluconazole may have immunomodulatory and salutary effects that extend beyond treatment of infection and that may not be readily ascertained by examining end points that evaluate rates of infection (17) . Future studies in the prevention of fungal infections therefore need to address identifying those at highest risk in order to maximize the likelihood of detecting an important difference in survival.
Despite controversy about the attributable mortality of candidal infections, most authors concur regarding the considerable financial implications of these infections. Generally, candidemia necessitates treatment with expensive antifungal agents and prolongs the length of stay in the ICU. Lelu et al. (27) observed that the development of candidemia nearly quadrupled the ICU length of stay (from 8 to 30 days). As noted above, Blot and colleagues failed to detect any mortality attributable to candidemia (5, 6) . However, these investigators reported that candidal bloodstream infections increased the ICU length of stay by 11 days and the duration of hospitalization outside the ICU by 13 days (5) . Unfortu-nately, investigators in only two trials in this meta-analysis systematically recorded information about resource utilization, and neither showed that fluconazole affected this outcome measure (12, 14) .
Since altering mortality may be too stringent a standard to apply to preventive interventions in critical care, evidence of an impact on resource utilization and economics can and should lead to changes in practice. Even though fluconazole administration decreased fungal infections, no data presently indicate that routine fluconazole prophylaxis in the SICU will yield savings. This discordance highlights the point that non-bloodstream fungal infections, which are reduced by fluconazole, may have limited clinical sequelae in the critically ill. Additional studies on fluconazole prophylaxis should proactively collect information on economic end points to provide more definitive information on this topic. Again, as with mortality, fluconazole may confer a morbidity benefit that has simply not been shown yet because the trials have enrolled populations that are either too heterogeneous or too small to allow definitive data to be gathered on this question.
Any intervention in critical care must balance benefits against risks. Because our analysis suggests that fluconazole prophylaxis has only limited value, clinicians need to evaluate the pitfalls associated with this approach. Specifically, this tactic could theoretically complicate treatment of fungal infections by creating selection pressure that favors the development of infections with nonalbicans Candida species or by promoting resistance among previously susceptible yeast. Notably, the study by Garbino et al. (15) combined fluconazole administration with a strategy of selective digestive decontamination (SDD). While antibacterial SDD is a well-accepted intervention in some SICUs, it may increase colonization with fungi (28 -32) . How fluconazole prophylaxis might further influence selection pressure in patients treated with SDD is not known. Moreover, in immunosuppressed patients, several centers have detected a shift in the distribution of isolates responsible for fungal infections after the institution of regular fluconazole prophylaxis. At the Fred Hutchinson Cancer Center, following the initiation of a fluconazole prophylaxis strategy, the most common candidal species re-sponsible for infection were C. glabrata, C. krusei, and C. parapsilosis (9) .
Although prophylactic fluconazole has generally decreased the overall rate of fungal infections in immunosuppressed subjects and thus is felt to be of value in this population, broader use of fluconazole has clearly had secondary effects. The fungal ecology of the ICU environment is clearly distinct, and trends seen outside the ICU may not be applicable to the ICU directly. Furthermore, because of the already high incidence of nonalbicans species recovered from critically ill patients, it may be difficult to detect if greater utilization of fluconazole will affect the distribution of fungal species. Pelz et al. (14) , however, explicitly focused on the implications of fluconazole prophylaxis on nonalbicans isolates and concluded that this was not associated with a shift toward these species. Similarly, Piarroux and co-workers (33) , in an observational analysis of preemptive fluconazole in high-risk patients colonized with Candida, reported that this strategy did not cause the emergence of nonalbicans yeast. In short, it is uncertain if and how greater use of fluconazole could affect the types and susceptibilities of Candida seen, and thus this must be considered as a potential but not proven concern.
Prior prophylaxis also exposes individual subjects to the possibility of superinfection with resistant strains of Candida. Safran et al. (34) noted that following institution of prophylactic fluconazole in their SICU, approximately 20% of patients receiving this agent suffered secondary mycoses, and 80% of these infections were with species inherently resistant to fluconazole. A recent epidemiologic analysis highlights this concern. Among 1,143 cases of fungal bloodstream infection, prior fluconazole exposure was associated with fluconazole resistance (7) . Likewise, in critically ill patients, infection with fluconazoleresistant Candida, independent of the particular species, doubles the risk for death (35) .
Might there be a clear set of patients who will profit from fluconazole prophylaxis? Crucial to any attempt to design future prophylactic studies will be clinically validated rules to identify those at highest risk and thus most likely to benefit. As noted earlier, the studies performed to date may simply have focused on the wrong population. Two potential rubrics for risk stratification include the colonization index developed by Pittet et al. and the clinical decision aides proposed by Ostrosky-Zeichner and coworkers (36, 37) . The colonization index incorporates the patient's clinical status with the number of sites from which Candida is recovered. This index has been retrospectively validated (33) . The clinical guideline approach recommended by Ostrosky-Zeichner et al. suggests that high-risk persons are those who remain in the ICU for 4 or more days and who either have a central catheter in place or are treated with antibiotics in addition to two of the following: use of parenteral nutrition, need for dialysis, recent major surgery, diagnosis of pancreatitis, treatment with systemic corticosteroids, or other use of immunosuppressives (37) . Although the incidence of invasive fungal infections is high in those identified by this clinical tool, the overall positive predictive value is low (approximately 10%) (37) .
Our analysis has several important limitations. First, there were few studies to review. To confirm our general conclusions and to attempt to correct for this shortcoming, we conducted a sensitivity analysis that included additional trials. Second, and as mentioned earlier, despite our enlarging the number of subjects studied, our sample size may still have been inadequate for detecting clinically important differences. On the basis of the pooled mortality rate from the studies in our meta-analysis, we estimate that any one single trial would have to enroll Ͼ2,000 patients in order to have 80% power to detect a 20% decline in mortality with fluconazole prophylaxis. Hence, the absence of proof of a benefit from fluconazole does not imply that we have proven the absence of any potential benefit.
Third, each trial in the meta-analysis was conducted in an academic teaching center; thus, it is unclear if these results are generalizable to other institutions. In addition, authors reported only ICU mortality rather than hospital mortality. Relatedly, there can be substantial variation in the distribution and burden of candidemia from one hospital to another. Therefore, our conclusion should not be extrapolated to any one center, and decisions about fluconazole prophylaxis should be examined in light of local data. In other words, if candidemia is a rare event in one specific SICU, it is unlikely that prophylaxis will lower the rate further.
Finally, there was both qualitative and quantitative heterogeneity in the trials, complicating pooling of the results. Specifically, differing dosing regimens were employed, and some studies used fluconazole regimens that others would consider treatment regimens rather than prophylaxis. Heterogeneity also arises from differing inclusion criteria and types of subjects evaluated. Nonetheless, we felt it appropriate to use meta-analytic techniques since the primary hypothesis tested in each of these trials dealt with prevention as defined by the study authors. To attempt to address this heterogeneity statistically, we employed a conservative random-effects model. Most important, however, meta-analysis has purposes other than simply providing more precision in the estimate of treatment effect. Meta-analysis serves to highlight the quality of the evidence in certain areas and aids in highlighting uncertainty. Meta-analysis additionally allows for exploratory and subgroup analyses that cannot otherwise be performed. In the case of fluconazole prophylaxis, without meta-analysis one could not systematically explore the impact of this intervention on fungemia or provide estimates of sample sizes needed for future trials.
In conclusion, fluconazole prophylaxis for critically ill surgical patients appears to decrease the rate of fungal infections. The effects of preventive fluconazole administration on both rates of fungemia and resource utilization are unclear. Fluconazole prophylaxis does not appear to improve survival in this setting. Further research directed at identifying very high-risk patients and focusing on mortality are required before the adoption of routine fluconazole prophylaxis in the SICU. 
